9/13/2021 7:05:02 AM
Alkermes To Present Two Posters On Investigational Immuno-oncology Candidate, Nemvaleukin Alfa At ESMO
9/9/2021 7:02:53 AM
Alkermes To Begin Accepting Applications For Annual Alkermes Pathways Research Awards Program On Sept. 13
8/2/2021 7:00:54 AM
Alkermes Gets FDA Fast Track Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma
7/28/2021 7:22:45 AM
Alkermes plc (ALKS) Has Raised Its FY21 EPS Estimate To 0.52 - 0.70 From 0.37 - 0.62
7/28/2021 7:22:10 AM
Alkermes plc (ALKS) Has Raised Its FY21 Revenue Estimate To $1,145 – $1,185 Mln From $1,100 – $1,170 Mln
7/28/2021 7:02:42 AM
Alkermes Plc Q2 GAAP EPS $0.01 And Non-GAAP EPS $0.30
6/30/2021 7:09:45 AM
Alkermes Presents New Data Analysis On Healthcare Resource Use Among Veterans With Alcohol Dependence At RSA Meeting
6/4/2021 9:19:53 AM
Alkermes Reports New Data From Its ARTISTRY Clinical Development Program For Nemvaleukin Alfa
6/1/2021 7:04:44 AM
Alkermes Announces FDA Approval Of LYBALVI For Schizophrenia And Bipolar I Disorder
5/20/2021 7:01:18 AM
Alkermes Appoints Emily Peterson Alva To Board
5/13/2021 7:02:46 AM
Alkermes To Begin Accepting Applications For Alkermes Inspiration Grants Program Beginning On May 20
5/3/2021 7:08:14 AM
Alkermes To Present Clinical Data And Outcomes Research From Psychiatry Portfolio During Mental Health Awareness In May
4/30/2021 7:02:19 AM
Alkermes Enters Agreement With Sarissa Capital; Grants Sarissa Right To Designate Director To Board